| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP, SGS |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | 99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Product Name | Sonwu Supply CAS 943319-70-8 Ponatinib Powder Ponatinib |
| CAS NO. | 943319-70-8 |
| MF | C29H27F3N6O |
| MW | 532.56 |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Appearance | White Powder |
| Certificate | ISO, SGS, GMP, HACCP |
| Assay Method | HPLC |
| Extraction Type | Solvent Extraction |
| Sample | Available |
| MOQ | 5g |
| Shelf life | 2 Years |
| Storage | Store in cool & dry place not freeze Keep away from strong light and heat |
1. Panatinib successfully suppressed the function of the BCR-ABL mutation in patients with refractory chronic myelogenous leukemia in a phase I clinical trial.
2. Panatinib not only inhibits BCR-ABL itself and its mutants at an effective concentration in clinical practice, but also inhibits FLT3 Kit in vitro FGFR1 and PDGFR alpha activity, with containing these receptors active forms of leukemia cell line experiment, we find that it can effectively inhibit receptor phosphorylation and cell proliferation, in patients with acute myeloid leukemia, for he are activated to restrain activity of FLT3 - ITD mutants of 30%, in MV4-11 (FLT3 ITD + / +) in acute myeloid leukemia cells, the, for, in less than 10 nmol/L concentrations can inhibit FLT3 signal and the induction of apoptosis.
3. Ponatinib inhibited all of the BCR-ABL mutant strains in the assay, and BCR-ABT315I inhibited bad cells in mice.
4. Ponatinib is an antidisease product. It was approved by FDA in December 2012 for adult chronic myelogenous leukemia (CML) and "Philadelphia chromosome positive" (PH +) acute lymphoblastic leukemia (ALL).
5. Ponatinib was approved in the European Union in July 2013 through a centralised approval process. Panatinib is the third generation of multi-target tyrosine kinase inhibitors. Typical api of multi-target tyrosine kinase inhibitors include sunitinib, imatinib, sorafenib and vataranib., for he (Ponatinib) can effectively inhibit the in vitro FGFR1-4 kinase activity, its IC50 alue concentration,2,18 2 and 8 nmol/L respectively, in the absence of interleukin - 3 cells, FGFR1, on behalf of, to curb cells - 4 kinase expression of IC50 alue concentration were 8 August 24 and 34 nmol/L, and tested in each cell, for inhibition of FGFR1-4 phosphorylation, its IC50 alue concentration is 39 29 32 and 39 nmol/L respectively tested on endometrial bladder Stomach and thymus in multiple cell lines FGFR inhibition.
| Other Hot-Selling Similar Products | ||||
| Capecitabine | Everolimus | Afatinib | Vandetanib | Gefitinib |
| Temozolomid | Rapamycin | Axitinib | Sorafenib tosylate | Cediranib |
| Cabozantinib | Selumetinib | Crizotinib | Sunitinib malate | Erlotinib |
| Crizotinib | Lapatinib | Debrafenib | Cabazitaxel | Ponatinib |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}